CD4 ((+) T细胞的转移加剧了免疫缺陷阿波利波蛋白E淘汰小鼠的动脉样硬化
X Zhou1, A Nicoletti, R Elhage
1Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Circulation
|January 11, 2000
概括
涉及CD4 ((+) T细胞的免疫反应促进动脉样硬化发展. 减少T细胞活性显著减少了小鼠模型中的动脉样硬化病变,突出了它们在疾病中的关键作用.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- 动脉样硬化病原体的产生
背景情况:
- 动脉样硬化涉及到对修饰性脂蛋白和微生物的免疫反应.
- 适应性免疫在动脉样硬化中的特定作用仍然不完全理解.
研究的目的:
- 调查特异性免疫对动脉样硬化进展的贡献.
- 阐明CD4 (((+) T细胞在动脉样硬化病变的发展中的作用.
主要方法:
- 交叉动脉样硬化易患的apoE的小鼠与免疫缺陷的scid/scid小鼠.
- 在后代和免疫能力强的对照中评估了大动脉脂肪链病变.
- 从apoE(-/-) 小鼠转移的CD4(+) T细胞到免疫缺陷接受者.
主要成果:
- 缺少适应性免疫力的后代显示,大动脉病变减少了73%.
- 在免疫缺陷小鼠中,CD4 ((+) T细胞的转移使病变增加了164%.
- 在病变中,T细胞透,干扰素-和I-A表达升高.
结论:
- CD4(+) T细胞是动脉样硬化中促进疾病免疫力的关键媒介.
- 特定的T细胞免疫力加剧了动脉样硬化病变的发展.
相关概念视频
Inflammation
46.6K
Overview
46.6K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


